Form 4: Acadia Pharmaceuticals Director Equity Update

Director Laura Brege exercised restricted stock units and received new equity grants in Acadia Pharmaceuticals.

Summary

• Director Laura Brege acquired 8,107 shares of common stock through the vesting of restricted stock units (RSUs) on May 29, 2026.
• Following the transaction, the director holds a total of 23,202 shares of common stock.
• The director received a new grant of 16,004 stock options with an exercise price of $21.66, vesting quarterly over one year.
• The director received a new grant of 9,311 RSUs, which vest in one year or at the next annual meeting, with receipt deferred.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Director maintains a significant equity stake of 23,202 shares, aligning interests with shareholders.
• Equity compensation structure incentivizes long-term retention and performance through vesting schedules.

Negatives

• None identified; this is a standard compensatory equity filing.

Risks

• Future value of stock options is dependent on the market price of ACAD exceeding the $21.66 exercise price.

Future Outlook

The director has elected to defer receipt of the 9,311 newly granted RSUs until the fifth anniversary of the grant, cessation of board service, or a change in control.

Management Comments

• The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard practice in the biopharmaceutical industry to ensure director alignment with long-term corporate governance and shareholder value creation.

Comparison to Industry Standards

• The use of RSU and stock option grants for board compensation is consistent with standard practices for mid-cap biotechnology companies.
• The vesting schedule of one year for director equity is typical for maintaining board stability.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from director alignment through equity ownership.

Next Steps

• Quarterly vesting of the 16,004 stock options over the next year.
• Vesting of 9,311 RSUs in one year or at the next annual meeting.

Key Dates

Keywords

ACAD, Acadia Pharmaceuticals, Form 4, Insider Trading, Equity Compensation, Director Compensation